中老年慢性乙型肝炎患者HBV DNA载量与不同部位骨密度的关系研究
Association between HBV DNA Load and Bone Mineral Density at Different Sites in Middle-Aged and Elderly Patients with Chronic Hepatitis B
DOI: 10.12677/acm.2026.161311, PDF,   
作者: 周歆雨, 祖 娜:青岛大学青岛医学院,山东 青岛;王十锦, 荆 雪, 孔心涓*:青岛大学附属医院消化内科,山东 青岛
关键词: 慢性乙型肝炎病毒载量骨密度中老年人Chronic Hepatitis B Viral Load Bone Density Middle-Aged and Elderly
摘要: 目的:探讨未经抗病毒治疗的中老年慢性乙型肝炎(CHB)患者HBV DNA载量与不同部位骨密度(BMD)之间的关系,并分析其影响的部位及性别差异,为骨质疏松的早期筛查与风险分层提供依据。方法:本研究采用横断面设计,回顾性纳入2014年1月至2024年1月期间在青岛大学附属医院同期完成HBV DNA检测与双能X线骨密度检查的未抗病毒治疗慢性乙型肝炎患者(绝经后女性和年龄 ≥ 50岁男性)共362例。根据HBV DNA水平(界值为2000 IU/mL)将患者分为高病毒载量组(n = 141)与低病毒载量组(n = 221)。收集并分析两组患者的一般临床资料、血清学指标以及腰椎、股骨颈和全髋的骨密度T值。统计学分析采用t检验、分层分析、线性回归和Spearman相关分析进行组间比较与变量关联性评估。结果:高病毒载量组患者的腰椎、股骨颈及全髋骨密度T值均显著低于低病毒载量组。年龄分层分析显示,高病毒载量对骨密度的负向影响在男性患者中存在于各年龄段的各部位,而在女性患者中主要局限于腰椎。多因素线性回归分析显示,在校正混杂因素后,高病毒载量仍是各部位骨密度下降的独立危险因素。性别分层分析表明,在男性患者中高病毒载量与各部位骨密度均显著相关,其中对股骨颈影响最大;而在女性患者中病毒载量高低仅与腰椎骨密度独立相关。相关性分析进一步证实,病毒载量与股骨颈骨密度的负相关性最强(r = −0.401),且在男性中这一关联尤为显著。结论:在未抗病毒治疗的中老年慢性乙型肝炎患者中,高HBV DNA载量是骨密度下降的独立危险因素,其影响呈现明确的性别模式:在男性中表现为跨年龄段、多部位的广泛影响,以股骨颈最为显著;在女性中则主要累及腰椎。本文为回顾性探索性结论,尚需前瞻性研究进一步验证。
Abstract: Objective: To investigate the relationship between HBV DNA load and bone mineral density (BMD) at different sites in middle-aged and elderly patients with chronic hepatitis B (CHB) who have not received antiviral therapy, and to analyze the site-specific and sex-specific differences of this impact, thereby providing a basis for early screening and risk stratification of osteoporosis. Methods: This cross-sectional study retrospectively enrolled 362 treatment-naive CHB patients (postmenopausal women and men aged ≥ 50 years) who concurrently underwent HBV DNA testing and dual-energy X-ray absorptiometry (DXA) at The Affiliated Hospital of Qingdao University between January 2014 and January 2024. Patients were divided into a high viral load group (n = 141) and a low viral load group (n = 221) based on an HBV DNA cutoff of 2000 IU/mL. General clinical data, serological markers, and BMD T-scores of the lumbar spine, femoral neck, and total hip were collected and analyzed. Statistical analyses included t-tests, stratified analysis, linear regression, and Spearman correlation for intergroup comparisons and association assessments. Results: BMD T-scores at the lumbar spine, femoral neck, and total hip were significantly lower in the high viral load group compared to the low viral load group. Age-stratified analysis revealed that the negative effect of high viral load on BMD was present across all age groups and sites in male patients, whereas in female patients, it was primarily confined to the lumbar spine. Multivariate linear regression analysis, after adjusting for confounders, confirmed that high viral load remained an independent risk factor for BMD reduction at all sites. Sex-stratified analysis indicated that in male patients, high viral load was significantly associated with lower BMD at all sites, with the strongest effect observed at the femoral neck. In contrast, in female patients, viral load was independently associated only with lumbar spine BMD. Correlation analysis further confirmed that viral load showed the strongest negative correlation with femoral neck BMD (r = −0.401), and this association was particularly pronounced in males. Conclusion: In treatment-naive middle-aged and elderly CHB patients, high HBV DNA load is an independent risk factor for decreased BMD. Its impact demonstrates a distinct sex-specific pattern: a widespread, multi-site effect across all age groups in men, most notably at the femoral neck, while primarily affecting the lumbar spine in women.
文章引用:周歆雨, 王十锦, 祖娜, 荆雪, 孔心涓. 中老年慢性乙型肝炎患者HBV DNA载量与不同部位骨密度的关系研究[J]. 临床医学进展, 2026, 16(1): 2493-2503. https://doi.org/10.12677/acm.2026.161311

参考文献

[1] Polaris Observatory Collaborators (2018) Global Prevalence, Treatment, and Prevention of Hepatitis B Virus Infection in 2016: A Modelling Study. The Lancet Gastroenterology & Hepatology, 3, 383-403.
[2] Zheng, H., Wang, Y., Wang, F.Z., et al. (2024) New Progress in HBV Control and the Cascade of Health Care for People Living with HBV in China: Evidence from the Fourth National Serological Survey, 2020. The Lancet Regional HealthWestern Pacific, 51, Article 101193. [Google Scholar] [CrossRef] [PubMed]
[3] Jeng, W.J., Papatheodoridis, G.V. and Lok, A.S.F. (2023) Hepatitis B. The Lancet, 401, 1039-1052. [Google Scholar] [CrossRef] [PubMed]
[4] Iloeje, U.H., Yang, H., Su, J., Jen, C., You, S. and Chen, C. (2006) Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load. Gastroenterology, 130, 678-686. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, C.J., Yang, H.I., Su, J., et al. (2006) Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DNA Level. Journal of the American Medical Association, 295, 65-73. [Google Scholar] [CrossRef] [PubMed]
[6] Songtanin, B., Chaisrimaneepan, N., Mendóza, R. and Nugent, K. (2024) Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections. Viruses, 16, Article 618. [Google Scholar] [CrossRef] [PubMed]
[7] Rong, Q., Zhang, L., Su, E., Li, J., Li, J., Liu, Z., et al. (2008) Bone Marrow-Derived Mesenchymal Stem Cells Are Capable of Mediating Hepatitis B Virus Infection in Injured Tissues. Journal of Viral Hepatitis, 15, 607-614. [Google Scholar] [CrossRef] [PubMed]
[8] Rehermann, B. and Nascimbeni, M. (2005) Immunology of Hepatitis B Virus and Hepatitis C Virus Infection. Nature Reviews Immunology, 5, 215-229. [Google Scholar] [CrossRef] [PubMed]
[9] NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. The Journal of the American Medical Association, 285, 785-795. [Google Scholar] [CrossRef] [PubMed]
[10] Min, C., Bang, W.J., Kim, M., Oh, D.J. and Choi, H.G. (2019) The Association between Hepatitis and Osteoporosis: A Nested Case-Control Study Using a National Sample Cohort. Archives of Osteoporosis, 14, Article No. 34. [Google Scholar] [CrossRef] [PubMed]
[11] Schiefke, I., Fach, A., Wiedmann, M., et al. (2005) Reduced Bone Mineral Density and Altered Bone Turnover Markers in Patients with Non-Cirrhotic Chronic Hepatitis B or C Infection. World Journal of Gastroenterology, 11, 1843-1847. [Google Scholar] [CrossRef] [PubMed]
[12] 黄陈恕, 汤荣睿, 易小翠. 慢性乙型肝炎与骨质疏松相关性初步探讨[J]. 中国骨质疏松杂志, 2016, 22(9): 1136-1139.
[13] 张静怡, 唐映梅. 慢性乙型肝炎病毒感染相关性骨质疏松[J]. 中华肝脏病杂志, 2023, 31(7): 760-764.
[14] Gill, U.S., Zissimopoulos, A., Al-Shamma, S., Burke, K., McPhail, M.J.W., Barr, D.A., et al. (2015) Assessment of Bone Mineral Density in Tenofovir-Treated Patients with Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk? Journal of Infectious Diseases, 211, 374-382. [Google Scholar] [CrossRef] [PubMed]
[15] Wei, M.T., Le, A.K., Chang, M.S., Hsu, H., Nguyen, P., Zhang, J.Q., et al. (2019) Antiviral Therapy and the Development of Osteopenia/Osteoporosis among Asians with Chronic Hepatitis B. Journal of Medical Virology, 91, 1288-1294. [Google Scholar] [CrossRef] [PubMed]
[16] Sajith, K.G., Kapoor, N., Shetty, S., Goel, A., Zachariah, U., Eapen, C.E., et al. (2018) Bone Health and Impact of Tenofovir Treatment in Men with Hepatitis-B Related Chronic Liver Disease. Journal of Clinical and Experimental Hepatology, 8, 23-27. [Google Scholar] [CrossRef] [PubMed]
[17] Chen, Y.Y., Fang, W.H., Wang, C.C., et al. (2019) Crosssectional Assessment of Bone Mass Density in Adults with Hepatitis B Virus and Hepatitis C Virus Infection. Scientific Reports, 9, Article No. 5069. [Google Scholar] [CrossRef] [PubMed]
[18] Loosen, S.H., Killer, A., Bock, H.H., Luedde, T., Roderburg, C. and Kostev, K. (2024) Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study. Journal of Clinical Medicine, 13, Article 6152. [Google Scholar] [CrossRef] [PubMed]
[19] Yang, Y., Zeng, J., Zhang, T., Wang, J., Fan, X., Wang, Q., et al. (2023) Association between Resolved Hepatitis B Virus Infection and Femoral and Spinal Bone Mineral Density in American Adults: A Cross-Sectional Study. Frontiers in Endocrinology, 14, Article 1237618. [Google Scholar] [CrossRef] [PubMed]
[20] 张东矗, 邓敦, 童郁, 许锴. 慢性乙肝患者伴骨质疏松症的危险因素研究[J]. 中华全科医学, 2020, 18(3): 432-434+445.
[21] Zhang, D.H. and Shao, J. (2025) Research Progress of Basing on Wnt/β-Catenin Pathway in the Treatment of Bone Tissue Diseases. Tissue Engineering Part B: Reviews, 31, 555-565. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, X., Li, Y., Huan, C., Hou, Y., Liu, R., Shi, H., et al. (2024) LncRNA NKILA Inhibits HBV Replication by Repressing NF-κB Signalling Activation. Virologica Sinica, 39, 44-55. [Google Scholar] [CrossRef] [PubMed]
[23] 任东方, 任镜静. 血清CRP、IL-6水平与慢性乙型肝炎病毒感染患者HBV-DNA病毒载量的相关性[J]. 中国实用医刊, 2023, 50(21): 29-32.
[24] 李淦, 曾奇, 刘海全. C反应蛋白与绝经后骨质疏松症相关性的Meta分析[J]. 中国综合临床, 2021, 37(6): 514-520.
[25] Gilbert, L., He, X., Farmer, P., Rubin, J., Drissi, H., van Wijnen, A.J., et al. (2002) Expression of the Osteoblast Differentiation Factor RUNX2 (Cbfa1/AML3/Pebp2αA) Is Inhibited by Tumor Necrosis Factor-α. Journal of Biological Chemistry, 277, 2695-2701. [Google Scholar] [CrossRef] [PubMed]
[26] Hou, J., He, C., He, W., Yang, M., Luo, X. and Li, C. (2020) Obesity and Bone Health: A Complex Link. Frontiers in Cell and Developmental Biology, 8, Article 600181. [Google Scholar] [CrossRef] [PubMed]
[27] Rogers, A., Saleh, G., Hannon, R.A., Greenfield, D. and Eastell, R. (2002) Circulating Estradiol and Osteoprotegerin as Determinants of Bone Turnover and Bone Density in Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 87, 4470-4475. [Google Scholar] [CrossRef] [PubMed]
[28] Cao, J.J. (2011) Effects of Obesity on Bone Metabolism. Journal of Orthopaedic Surgery and Research, 6, Article No. 30. [Google Scholar] [CrossRef] [PubMed]